Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AbbVie
Astellas Pharma Inc
Amgen
Merck Sharp & Dohme LLC
AbbVie
Actuate Therapeutics Inc.
Eli Lilly and Company
AstraZeneca
QuantumLeap Healthcare Collaborative
Revolution Medicines, Inc.
Hoffmann-La Roche
Norwegian University of Science and Technology
Gustave Roussy, Cancer Campus, Grand Paris
GlaxoSmithKline
Università Vita-Salute San Raffaele
University of Kentucky
Tesaro, Inc.
AbbVie
Weill Medical College of Cornell University
AbbVie
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Tesaro, Inc.
AbbVie
Sanofi
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
DEKA Biosciences
Mario Negri Institute for Pharmacological Research
Shandong Cancer Hospital and Institute
Northwell Health
Inspirna, Inc.
Spanish Lung Cancer Group
Ohio State University Comprehensive Cancer Center
Blueprint Medicines Corporation
GlaxoSmithKline
Eli Lilly and Company
iTeos Therapeutics
Cantargia AB
University of California, San Diego
MedImmune LLC
The First Affiliated Hospital of Guangzhou Medical University
Kyowa Kirin Co., Ltd.
Zhongnan Hospital
Nanfang Hospital, Southern Medical University
Loyola University
Blueprint Medicines Corporation
Merck Sharp & Dohme LLC